BLA 208583 · Novo
Xultophy 100/3.6
Insulin Degludec, Liraglutide · Subcutaneous · Insulin Analog; GLP-1 Receptor Agonist
Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Nov 21, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
212
87 Phase 3, 8 recruiting
FAERS reports
1,658
1,268 serious, 90 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide, one of the components of XULTOPHY 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13 )] . • XULTOPHY 100/3.6 is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of XULTOPHY 100/3.6 and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent...
What it is approved for
From the label in effect Oct 14, 2025.
XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions ( 5.5 )]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. XULTOPHY 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : ( 1 ) • Coadministration with any other product containing liraglutide or another GLP-1 receptor agonist is not recommended. • Not recommended for the treatment of diabetic ketoacidosis. • Has not been studied in combination with prandial insulin.
Mechanism: XULTOPHY 100/3.6 XULTOPHY 100/3.6 is a combination product consisting of insulin degludec and liraglutide. Insulin degludec The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. Liraglutide Liraglutide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 8, 2019 Supplement 12 · Efficacy LetterLabel
- Feb 27, 2019 Supplement 10 · Efficacy LabelLetter
- Feb 27, 2019 Supplement 8 · Efficacy LetterLetter
- Feb 27, 2019 Supplement 11 · Efficacy LabelLetter
- Feb 1, 2019 Supplement 3 · Efficacy LetterLabel
- Feb 1, 2019 Supplement 2 · Efficacy LetterLabel
- Nov 21, 2016 Original approval · Type 4 - New Combination LetterLabelReview
1 products under this application
- XULTOPHY 100/3.6 · INSULIN DEGLUDEC 300 UNITS/3ML; LIRAGLUTIDE 10.8MG/3ML (100 UNITS/ML · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Degludec" as an intervention, any sponsor and status, largest first.
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01959529 · 7,637 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2016
Drug: insulin degludec; insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Montgomery, Alabama; Gilbert, Arizona · 446 sites in all
- Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01336023 · 1,663 participants · Start May 23, 2011 · Primary completion May 24, 2012
Drug: insulin degludec/liraglutide; insulin degludec and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Anaheim, California; Bermuda Dunes, California · 302 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03078478 · 1,609 participants · Start Mar 13, 2017 · Primary completion Feb 13, 2019
Drug: Insulin degludec; Insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Anniston, Alabama; Birmingham, Alabama; Chandler, Arizona · 229 sites in all
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03882970 · 1,444 participants · Start Apr 1, 2019 · Primary completion Dec 11, 2020
Drug: Tirzepatide; Insulin Degludec · For: Type 2 Diabetes Mellitus
Sites: Little Rock, Arkansas; Fresno, California; Huntington Park, California · 122 sites in all
- A Study of LY900014 in Participants With Type 1 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03214367 · 1,392 participants · Start Jul 17, 2017 · Primary completion Sep 6, 2018
Drug: LY900014; Insulin Lispro and 2 more · For: Type 1 Diabetes Mellitus
Sites: Mobile, Alabama; Concord, California; Escondido, California · 172 sites in all
- Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03268005 · 1,264 participants · Start Sep 19, 2017 · Primary completion Jan 7, 2019
Drug: Faster-acting insulin aspart; Insulin aspart and 2 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Concord, California; Fresno, California; Fullerton, California · 167 sites in all
- Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02500706 · 1,108 participants · Start May 4, 2016 · Primary completion Jul 17, 2017
Drug: Faster-acting insulin aspart; insulin aspart and 1 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Tucson, Arizona; Concord, California; Encino, California · 152 sites in all
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04760626 · 1,085 participants · Start Mar 1, 2021 · Primary completion Aug 12, 2022
Drug: Insulin icodec; Insulin Glargine 100U/mL and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Guntersville, Alabama; Gilbert, Arizona · 311 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased192
- nausea122
- acute kidney injury88
- diarrhoea87
- vomiting87
- hypoglycaemia73
- glycosylated haemoglobin increased62
- lactic acidosis58
- decreased appetite53
- asthenia50
- dizziness48
- hyperglycaemia47
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 3 |
| 2017 | 125 |
| 2018 | 229 |
| 2019 | 198 |
| 2020 | 150 |
| 2021 | 202 |
| 2022 | 149 |
| 2023 | 116 |
| 2024 | 166 |
| 2025 | 217 |
| 2026 | 103 |
Recalls
1 FDA enforcement reports for this application.
Mar 22, 2021 · Class I · Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xultophy 100-3.6 (Insulin Degludec/Liraglutide)
2024 spending
$91.3M
Beneficiaries
13,672
57,197 claims
Per beneficiary
$6,675
$81.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $71,921,892 |
| 2021 | $75,755,898 |
| 2022 | $77,994,459 |
| 2023 | $91,415,961 |
| 2024 | $91,255,682 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
Zeitler P, Galindo RJ, Davies MJ, et al. · Diabetes Care 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I, Asong M, Desouza C, et al. · JAMA 2023 · Clinical Trial, Phase III, Equivalence Trial
- Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.
Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · Lancet Diabetes Endocrinol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A, Asong M, Franek E, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Multicenter Study
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, et al. · Lancet 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.